Pharming Group N.V.
PHAR
Positions held
Your positionsPHAR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $674.52M | Enterprise value | $629.53M | Trailing P/E | 73.31 | Forward P/E | 31.04 |
| PEG | — | Price / book | 2.49 | Beta | 0.07 | Dividend yield | 0.00% |
| Revenue growth | -3.2% | Earnings growth | -62.9% | Gross margin | 86.5% | Operating margin | 1.5% |
| Profit margin | 2.5% | ROE | 3.6% | ROA | 3.5% | Debt / equity | 0.42 |
| Current ratio | 3.01 | Free cash flow | $37.69M | Analyst recommendation | strong_buy | Mean target | $34.35 |
| 52w high | $21.34 | 52w low | $9.44 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $90.2M | $72.4M | $107M | $97.3M | $93.2M | — |
| Op margin | -0.1% | -7.3% | 1.9% | 16.2% | 9.7% | — |
| Net income | $1.6M | -$5.2M | $5.3M | $7.5M | $4.7M | — |
| Gross margin | 83.9% | 90.8% | 80.2% | 92.7% | 90.4% | — |
| Gross profit | $75.7M | $65.8M | $85.4M | $90.2M | $84.2M | — |
| Operating income | -$0.1M | -$5.3M | $2.0M | $15.8M | $9.0M | — |
- Revenue +25% vs prior quarter ($90M vs $72M).
- Gross margin 83.9% (was 90.8% prior quarter).
- Operating margin expanded to -0.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $376M | $297M | $245M | $206M | — |
| Op margin | 5.6% | -1.2% | -9.1% | 4.8% | — |
| Net income | $2.9M | -$11.8M | -$10.5M | $13.7M | — |
| Gross margin | 87.9% | 88.1% | 89.7% | 91.5% | — |
| Gross profit | $331M | $262M | $220M | $188M | — |
| Operating income | $20.9M | -$3.7M | -$22.3M | $9.9M | — |
Headlines — watch
• [WARN · fundamentals] Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
News
2026-09-29 · Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday
2026-09-29 · Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs
2026-09-29 · Pharming announces CEO transition
2026-09-16 · Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?
2026-09-11 · FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
2026-09-09 · Pharming Group to participate in September investor conferences
2026-08-14 · Form 8.3
2026-08-11 · Form 8.3
2026-08-04 · Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Price (daily)
Full chart · RSI · MACD · patterns